Last reviewed · How we verify
Prismocitrate 18
Prismocitrate 18 is a citrate-based anticoagulant used in regional citrate anticoagulation (RCA) for extracorporeal therapies.
Prismocitrate 18 is a citrate-based anticoagulant used in regional citrate anticoagulation (RCA) for extracorporeal therapies. Used for Regional citrate anticoagulation for continuous renal replacement therapy (CRRT) in critically ill patients, Anticoagulation for extracorporeal blood purification therapies.
At a glance
| Generic name | Prismocitrate 18 |
|---|---|
| Also known as | Regional Citrate Anticoagulation (RCA) |
| Sponsor | Vantive Health LLC |
| Drug class | Regional anticoagulant / Citrate-based anticoagulant |
| Target | Ionized calcium (Ca2+) |
| Modality | Small molecule |
| Therapeutic area | Nephrology / Critical Care |
| Phase | Phase 3 |
Mechanism of action
Prismocitrate 18 chelates ionized calcium in the blood, preventing coagulation during dialysis or other extracorporeal treatments. The citrate is metabolized by the liver to bicarbonate, restoring systemic calcium levels post-treatment. This approach provides anticoagulation localized to the extracorporeal circuit while minimizing systemic anticoagulation effects.
Approved indications
- Regional citrate anticoagulation for continuous renal replacement therapy (CRRT) in critically ill patients
- Anticoagulation for extracorporeal blood purification therapies
Common side effects
- Hypocalcemia
- Metabolic alkalosis
- Hypernatremia
- Citrate accumulation (in hepatic dysfunction)
Key clinical trials
- Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT (PHASE3)
- Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT) (PHASE3)
- Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy (PHASE4)
- Magnesium Balance of Citrate-based Continuous Venovenous Hemofiltration, Effect of Citrate Dose. (NA)
- A Study on the Efficacy and Safety of Continuous Renal Replacement Therapy (CVVHDF) Using a Commercial Citrate-containing Replacement Fluid (Prismocitrate 18/0) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prismocitrate 18 CI brief — competitive landscape report
- Prismocitrate 18 updates RSS · CI watch RSS
- Vantive Health LLC portfolio CI